NEW IN 2018: CLEVELAND CLINIC JOINS I-CORPS@OHIO PROGRAM

Cleveland Clinic Lerner Research Institute. March 15, 2018

Cleveland Clinic has been named to the Governance Board of I-Corps@Ohio, a statewide program to assist faculty and graduate students from Ohio universities and colleges to validate the market potential of their technologies and launch startup companies. Ofer Reizes, PhD, Staff, Lerner Research Institute Department of Cellular and Molecular Medicine, and Director, Research Core Services, and Mark Low, Managing Director of the Global Cardiovascular Innovation Center and NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic, will serve as program officers.

Funded by the Ohio Department of Higher Education, I-Corps@Ohio is modeled after the National Science Foundation's Innovation Corps (I-Corps) program, which is proven to increase innovation, entrepreneurship and industry collaboration. The seven-week summer program—conducted and guided by The Ohio State University, College of Engineering's Center for Design and Manufacturing Excellence—helps investigators navigate the process of bringing new technology to market. Instructors guide participants through a series of in-person and virtual seminars that help them identify potential need for their technology, anticipate and address problems and more. Since its development in 2015, more than 50 research teams have completed the program.

Cleveland Clinic has implemented I-Corps programs with its NCAI cohorts and provided instructional support to other institutions running I-Corps-inspired programs. This past experience, as well as Cleveland Clinic's strong commercialization and research arms, will help advance the I-Corps@Ohio mission.
"This is a wonderful program, and we are proud and excited to be part of it," said Dr. Reizes. "It is helping to maximize return on research investments not only by developing cutting-edge devices and technologies that will help people and patients, but by educating the workforce and creating jobs and productive new companies."

As part of the Governance Board, Cleveland Clinic will help provide broad oversight, including monitoring the program's direction, establishing policies and setting and evaluating programmatic goals, among other responsibilities. I-Corps@Ohio also recently announced that the program has secured state-awarded funding for the next three years.

"Cleveland Clinic has a long history of success in innovation and commercialization, especially related to biomedical technology and life sciences," commented Mark Low. "We're eager to bring this knowledge and experience to the table to help young investigators from many different fields of research."

Dr. Reizes holds the Laura J. Fogarty Endowed Chair for Uterine Cancer Research.